PMID- 14666473
OWN - NLM
STAT- MEDLINE
DCOM- 20031224
LR  - 20190710
IS  - 1531-5037 (Electronic)
IS  - 0022-3468 (Linking)
VI  - 38
IP  - 12
DP  - 2003 Dec
TI  - A role of cytokines in OK-432 injection therapy for cystic lymphangioma: an 
      approach to the mechanism.
PG  - 1806-9
AB  - PURPOSE: This study examines cytokine levels of aspirates from cystic 
      lymphangiomas after injection of OK-432 and over the course of several weeks to 
      better understand the process of tumor regression. METHODS: Fluids aspirated from 
      lymphangioma cysts of 3 patients were collected sequentially before and after 
      OK-432 injection. Mononuclear cells (MNCs) were separated and cultured with or 
      without OK-432. Vascular endothelial growth factor (VEGF), soluble VEGF receptor 
      1 (sVEGFR1), sVEGFR2, transforming growth factor beta-1 (TGF-beta1), interleukin 
      (IL)-6, IL-8, IL-12+p40, tumor necrosis factor alpha (TNF-alpha) and interferon 
      gamma (IFN-gamma) levels in the supernatants of the aspirates and the culture 
      supernatants of MNCs were then measured by ELISA. RESULTS: The aspirates 
      exhibited a marked elevation in IL-6, IL-8, VEGF, and TGF-beta1 levels for a few 
      weeks after the OK-432 injection. IL-6, IL-8, IL-12+p40, TNF-alpha, and IFN-gamma 
      levels were elevated in the culture supernatants of the MNC cultured with OK-432 
      for up to 9 days. All the tumors regressed significantly, with sclerotic change, 
      within 3 months after OK-432 injection. CONCLUSIONS: Cytokine production is 
      maintained for a few weeks after OK-432 injection. Fibrotic changes may be 
      another main mechanism in tumor regression in addition to cytotoxic effects on 
      lymphangioma cells. A close relationship between cytokines from intracystic cells 
      and lymphangioma cells is suggested.
FAU - Fujino, Akihiro
AU  - Fujino A
AD  - Department of Surgery, Keio University School of Medicine, Japan.
FAU - Moriya, Yoichiro
AU  - Moriya Y
FAU - Morikawa, Yasuhide
AU  - Morikawa Y
FAU - Hoshino, Ken
AU  - Hoshino K
FAU - Watanabe, Toshihiko
AU  - Watanabe T
FAU - Shimojima, Naoki
AU  - Shimojima N
FAU - Kitajima, Masaki
AU  - Kitajima M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Pediatr Surg
JT  - Journal of pediatric surgery
JID - 0052631
RN  - 0 (Cytokines)
RN  - 39325-01-4 (Picibanil)
SB  - IM
MH  - Child, Preschool
MH  - Cytokines/*analysis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Infant, Newborn
MH  - Injections
MH  - Lymphangioma, Cystic/*drug therapy/immunology
MH  - Male
MH  - Picibanil/immunology/*therapeutic use
EDAT- 2003/12/11 05:00
MHDA- 2003/12/25 05:00
CRDT- 2003/12/11 05:00
PHST- 2003/12/11 05:00 [pubmed]
PHST- 2003/12/25 05:00 [medline]
PHST- 2003/12/11 05:00 [entrez]
AID - S0022346803006390 [pii]
AID - 10.1016/j.jpedsurg.2003.08.041 [doi]
PST - ppublish
SO  - J Pediatr Surg. 2003 Dec;38(12):1806-9. doi: 10.1016/j.jpedsurg.2003.08.041.